Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results are anticipated in the first quarter of 2025. This trial will guide further research on TRP-8803, an IV-infused psilocin, expected to offer improved efficacy, safety, faster onset, precise control, and reduced intervention duration compared to oral psilocybin. IBS affects up to 20% of Australians and 15% of the US population and represents a significant unmet medical need, impacting productivity and quality of life. Tryptamine Therapeutics aims to address this need by exploring the gut-brain relationship through their ongoing and future clinical trials. Gilligan highlighted the collaboration with MGH, noting its prestigious reputation and significant interest in psychedelic compounds for treating unmet medical needs. Tryptamine Therapeutics is also advancing clinical trials for other conditions, including binge eating disorder and fibromyalgia. #ProactiveInvestors #ASX #TryptamineTherapeutics #IBS #ClinicalTrial #Psilocybin #TRP8802 #MassGeneralHospital #MGH #Harvard #GutBrainRelationship #Psychotherapy #TRP8803 #PsychedelicResearch #UnmetMedicalNeed #Productivity #QualityOfLife #Biotech #HealthcareInnovation #MentalHealth #BingeEatingDisorder #Fibromyalgia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews